Study of YSQTG with immunotherapy and chemo for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a Chinese herbal formula (YSQTG) combined with standard immunotherapy and chemotherapy for people newly diagnosed with extensive-stage small cell lung cancer. The goal is to see if adding YSQTG improves outcomes for patients with a specific traditional Chinese medicine pattern.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have extensive-stage small cell lung cancer (cancer that has spread widely in the lung or to other parts of the body).
- You have not had any previous cancer treatment like chemotherapy, immunotherapy, or radiation for this cancer.
- You are planning to receive at least 2 cycles of a standard treatment that combines immunotherapy, platinum chemo, and etoposide.
- You have not had any other type of cancer in the past or currently.
- You are 18 years or older and your doctor expects you to live at least 3 more months.
- You feel well enough to do daily activities (KPS score of 60 or higher) and can complete questionnaires.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an herbal granule (YSQTG) to standard chemotherapy with or without immunotherapy helps patients with a specific type of advanced esophageal cancer. It focuses on people whose cancer is stage III to IVa and who have not had treatment yet.
This trial tests a new combination of an immunotherapy drug (QL1706) plus chemotherapy given before and after surgery for people with certain stages of non-small cell lung cancer (NSCLC). The goal is to see if this approach helps shrink the tumor and improves outcomes.
This trial tests if adding a Chinese herbal formula (BaiDiZiYin ShenQiYiFei) to standard tuberculosis drugs helps improve symptoms like shortness of breath, fatigue, and coughing. It may be helpful for people diagnosed with pulmonary TB who also have signs of Qi and Yin deficiency (a traditional Chinese medicine pattern).
This trial tests a new combination of an immunotherapy drug (QL1706) with standard chemotherapy for people whose lung cancer has a specific genetic change (SMARCA4 deficiency). The goal is to see if this combination can shrink tumors and improve outcomes for this particular group of patients.
This trial tests a new drug called QL1706 combined with chemotherapy for people with non-small cell lung cancer that has spread or come back after previous treatment with an immunotherapy drug (PD-1/PD-L1 inhibitor) plus chemotherapy. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of an injectable herbal medicine (Shenqi Fuzheng), an immunotherapy drug (PD-1 inhibitor), and chemotherapy before surgery for early-stage lung cancer. The goal is to see if this approach can shrink tumors and improve the immune system's response, potentially leading to better outcomes.
Hear when a new Extensive-stage Small Cell Lung Cancer (SCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.